Association of concentration of asbestos and asbestos-like fibers with the patient's survival and the binding capacity of lung parenchyma to galectin-1 and natural alpha-galactoside- and alpha-mannoside-binding immunoglobulin G subfractions from human serum.
Our aim in this study was to search for lung parenchyma alterations associated with asbestos and/or asbestos-like fiber concentration. This was done by means of immuno- or glycohistochemistry. The hot-ashing technique determined the asbestos and asbestos-like fiber concentrations in the lung tissues of 100 patients of whom 52 were treated for primary lung and 25 for secondary lung tumors; fiber concentration was also measured for 23 patients whose disease was benign. The results were correlated to smoking habits, survival of the patients, and expression of binding capacities for endogenous lectins, natural carbohydrate-binding and lectin-specific antibodies. The cohort with proven asbestos exposure revealed a mean fiber concentration 114 f/g compared to 95 f/g in the non-exposed group. An increased asbestos fiber concentration was correlated to galectin-1-binding and the presence of epitopes for natural immunoglobulin G subfractions with selectivity to alpha-galactosides and alpha-mannosides. The survival of patients with primary and secondary lung tumors was negatively associated with the fiber concentration. The data indicate that increased presence of asbestos is correlated with an alteration of defined glycohistochemical features of alveolar lining cells.
Kayser
K
K
Department of Pathology, Thoraxklinik, Heidelberg, Germany. klkayser@lung.de
Seemann
C
C
André
S
S
Kugler
C
C
Becker
C
C
Dong
X
X
Kaltner
H
H
Gabius
H J
HJ
D000328:Adult; D001194:Asbestos / Q000378:metabolism*; D001195:Asbestosis / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D018797:Cell Cycle Proteins; D005260:Female; D005697:Galactosides / Q000276:immunology / Q000378:metabolism*; D037483:Galectin 1; D006388:Hemagglutinins / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007124:Immunoenzyme Techniques; D007074:Immunoglobulin G / Q000276:immunology / Q000378:metabolism*; D008168:Lung / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D008175:Lung Neoplasms / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D008297:Male; D008362:Mannosides / Q000276:immunology / Q000378:metabolism*; D008654:Mesothelioma / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D008875:Middle Aged; D019016:Mineral Fibers; D011650:Pulmonary Alveoli / Q000378:metabolism / Q000473:pathology; D000075383:S100 Calcium Binding Protein A6; D009418:S100 Proteins / Q000276:immunology / Q000378:metabolism; D015996:Survival Rate
D018797:Cell Cycle Proteins; D005697:Galactosides; D037483:Galectin 1; D006388:Hemagglutinins; D007074:Immunoglobulin G; D008362:Mannosides; D019016:Mineral Fibers; D000075383:S100 Calcium Binding Protein A6; D009418:S100 Proteins; C055351:S100A6 protein, human; D001194:Asbestos